UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer
AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Boehringer eyes H2 drug launches after strong H1 growth
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,
GSK adds EU to Blenrep checklist as FDA sets new PDUFA date
GSK has added the EMA to the list of regulatory bodies approving Blenrep for multiple myeloma, but whether the FDA is next is still an open question.
AZ boasts phase 3 win for self-administered gMG drug
Alexion has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment for gMG.
mRNA ‘wake-up call’ shows promise as universal cancer vaccin...
Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint inhibitor immunotherapy, significantly boosted anti-tumour activit
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Revolutionising Clinical Trials: Evolution Summit 2025 Retur...
Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers
Welcome to the 3rd Spatial Biology for Drug Development Summ...
Transforming Research & Development with Faster, More Precise Spatial Insights
2nd Hit ID Summit
Why prioritise your hit discovery game? Finding the right chemical start points is crucial to help you save time and costs in the long run.
Unlocking the Potential of Targeting the Innate Immune Syste...
Ready to Catalyze the Next Wave of Inflammasome Therapies?
The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...